We have observed
2 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after October 15, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Mutant calreticulin for the diagnosis of myeloid malignancies
4'-AZIDO, 3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES AS INHIBITORS OF HCV RNA REPLICATION